Fagan Associates’s Tvardi Therapeutics TVRD Stock Holding History

Fagan Associates’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-822	Closed	-$455K	–	110
2017 Q2	$455K	Buy	+822	New	+$522K	0.24%	80

Other funds holding TVRD

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fagan Associates's TVRD Position: Q3 2017 in Review

Fagan Associates sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 822 shares — an estimated $455K sold.

Fagan Associates first reported a position in TVRD in Q2 2017 and held it in 1 quarter. The position peaked at $455K in Q2 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

Fagan Associates reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
Fagan Associates sold 822 Tvardi Therapeutics shares in Q3 2017, an estimated $455K.
Fagan Associates first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 1 quarter.
Fagan Associates's Tvardi Therapeutics position peaked at $455K in Q2 2017.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Fagan Associates's 13F filing for Q3 2017, filed 13 Nov 2017.